Ensysce Biosciences financials
$0.4170+3.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $961.0K | $1.9M | $493.1K | $1.4M | $1.3M | $1.3M | $3.4M | $181.8K | $305.7K | $515.0K | $435.4K |
| Gross profit | $1.2M | $961.0K | $1.9M | $493.1K | $1.4M | $1.3M | $1.3M | $3.4M | $181.8K | $305.7K | $515.0K | $435.4K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.8M | -$2.0M | -$3.6M | $644.7K | -$2.0M | -$1.8M | -$3.2M | -$2.7M |
| Net income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.7M | -$1.9M | -$3.6M | $661.8K | -$2.0M | -$3.1M | -$3.5M | -$2.7M |
| Net margin | −220.8% | −370.1% | −147.0% | −756.3% | −126.4% | −147.4% | −273.4% | 19.4% | −1082.4% | −1019.5% | −680.4% | −617.8% |
| Diluted EPS | $-0.20 | $-0.52 | $-0.74 | $-1.29 | $-0.79 | $-1.39 | $-3.06 | $1.00 | $-3.35 | $-8.21 | $-19.90 | $-13.05 |
| EBITDA | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.8M | -$2.0M | -$3.6M | $644.7K | -$2.0M | -$1.8M | -$3.2M | -$2.7M |
| Operating cash flow | -$2.0M | -$3.5M | -$1.5M | -$1.9M | -$2.7M | -$1.7M | -$764.1K | -$1.0M | -$2.3M | -$3.4M | -$1.8M | -$2.3M |
| Free cash flow | -$2.0M | -$3.5M | -$1.5M | -$2.0M | -$2.7M | -$1.7M | -$764.1K | -$1.0M | -$2.3M | -$3.4M | -$1.8M | -$2.3M |
| Diluted shares | 13.0M | 6.8M | 3.7M | 2.9M | 2.2M | 1.4M | 1.2M | 0.7M | 0.6M | 0.4M | 0.2M | 0.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $676.7K | $745.5K | $4.3M | $1.7M | $2.2M | $3.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $196.8K | $245.8K | $306.7K | $387.7K | $424.5K | $257.4K |
| Total assets | $3.0M | $2.2M | $7.5M | $3.2M | $5.6M | $4.6M |
| Total liabilities | $4.1M | $2.8M | $4.6M | $2.3M | $2.5M | $1.9M |
| Shareholders' equity | -$1.1M | -$669.0K | $2.9M | $874.7K | $3.1M | $2.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology